Traders should monitor for follow-up trial updates, potential trial expansion or fast-track designation, and any signs of partnership interest, as these data may position darlifarnib as a meaningful combination therapy in refractory RCC. The stock may react positively to further de-risking of the program.
Price Chart
Executive Summary
Kura Oncology announced preliminary clinical data from a subset of patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib, showing a 44% objective response rate and 94% disease control rate with its investigational combination of darlifarnib and cabozantinib. The results suggest potential to overcome resistance to VEGF TKI therapy in a heavily pretreated population, with durable responses observed and a manageable safety profile. The data were presented at IKCS: Europe and discussed in a virtual investor event.
Key Facts
- Preliminary data from 16 ccRCC patients previously treated with cabozantinib showed a 44% objective response rate (ORR) and 94% disease control rate (DCR).
- Tumor shrinkage occurred in 75% of patients, with reductions ranging from 32% to 47% among responders.
- Treatment durations ranged up to 56 weeks, with one-third of patients still on therapy at data cutoff.
- Darlifarnib is being evaluated in combination with cabozantinib in the ongoing FIT-001 trial, with dose expansion underway.
- Virtual investor event held on April 17, 2026, to discuss findings.
Financial Impact
No direct financial figures disclosed, but strong clinical data may enhance valuation and partnership potential.
Risk Factors
- Data are preliminary and from a small subset (n=16), with limited statistical power.
- Future clinical trials may not replicate these results, and regulatory approval is not guaranteed.
- Competition in the RCC space is intense, with multiple existing and emerging therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276007 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access